Synapse - Arielle Elkrief

Results (43)

Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer

Journal Article

Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Combination of MDM2 and targeted kinase inhibitors results in prolonged tumor control in lung adenocarcinomas with oncogenic tyrosine kinase drivers and MDM2 amplification

Journal Article

Elkrief, A.; Odintsov, I.; Smith, R. S.; Vojnic, M.; Hayashi, T.; Khodos, I.; Markov, V.; Liu, Z.; Lui, A. J. W.; Bloom, J. L.; more...
JCO Precision Oncology (2024)

Fulltext@MSK | Save

Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%–89%) versus very high (≥90%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab

Journal Article

Ricciuti, B.; Elkrief, A.; Lin, J.; Zhang, J.; Alessi, J. V.; Lamberti, G.; Gandhi, M.; Di Federico, A.; Pecci, F.; Wang, X.; more...
JTO Clinical and Research Reports (2024)

Fulltext@MSK | Save

Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade

Meeting Abstract

Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

TTF-1 negativity as a biomarker of outcomes to immunotherapy, chemoimmunotherapy, and KRAS G12C inhibitors in lung adenocarcinoma

Meeting Abstract

Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Shaverdian, N.; Ricciuti, B.; Alessi, J. V. M.; De Giglio, A.; Pecci, F.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Journal Article

Elkrief, A.; Méndez-Salazar, E. O.; Maillou, J.; Vanderbilt, C. M.; Gogia, P.; Desilets, A.; Messaoudene, M.; Kelly, D.; Ladanyi, M.; Hellmann, M. D.; more...
npj Precision Oncology (2024)

Fulltext@MSK | Save

Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation

Journal Article

Elkrief, A.; Waters, N. R.; Smith, N.; Dai, A.; Slingerland, J.; Aleynick, N.; Febles, B.; Gogia, P.; Socci, N. D.; Lumish, M.; more...
Cancer Immunology Research (2024)

Fulltext@MSK | Save

Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer

Journal Article

Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
The Oncologist (2023)

Fulltext@MSK | Save

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

Journal Article

Alessi, J. V.; Price, A.; Richards, A. L.; Ricciuti, B.; Wang, X.; Elkrief, A.; Pecci, F.; Di Federico, A.; Gandhi, M. M.; Lebow, E. S.; more...
Journal for ImmunoTherapy of Cancer (2023)

Fulltext@MSK | Save

Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer

Journal Article

Thummalapalli, R.; Ricciuti, B.; Bandlamudi, C.; Muldoon, D.; Rizvi, H.; Elkrief, A.; Luo, J.; Alessi, J. V.; Pecci, F.; Lamberti, G.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save